focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Re-rating is justified. Am thinking of 20p initially.
Expect results to be substantial - but realistic
Yes - As usual we remain totally under the radar, but this will not always be the case.
We are now in Australia, so that is something new, and gradually Steriwave will gain recognition throughout the World.
As we await the 2023 results, I was reminded of an item in the 2022 results:
"Financial Highlights
· Revenues of $0.6 million (2021: $2.6 million). The decrease was anticipated and primarily due to the loss of pandemic-related sales to the meat processing plants as vaccinations became available."
If the contract with meat processing plants was worth say $2m, the potential revenues that could be generated from the range of opportunities that are now being developed must be significant. Even if the 2023 results disappoint some people, I am optimistic about the longer term outlook.
Currently
Not long to wait for results now
Ondine Biomedical Inc on Monday announced that Steriwave has been used for the first time in an Australian hospital.
The Vancouver-based life sciences company said that Mater Hospital in North Sydney has become the first Australian hospital to start using Steriwave for the prevention of hospital-acquired infections.
Medical Oncologist Frances Boyle said: "We are very pleased to be the first hospital in Australia to have the Steriwave nasal decolonization system. The pathogens patients carry have long been known to cause hospital-acquired infections, especially for the weak and immunocompromised. Having a rapid non-antibiotic approach to decolonizing the nose - a major source of infection transmission - is a benefit to our patients."
Steriwave is a light-activated antimicrobial which employs patented nasal photodisinfection technology to eliminate bacteria, fungi and viruses located on human tissues.
According to Ondine, surgical site infections are "one of the most significant complications in cardiac surgery patients and are strongly associated with poorer prognosis".
This comes after Ondine announced earlier this month that Steriwave had been approved by HCA Healthcare UK for use in its healthcare facilities.
Not much reaction to more good news. Taken a small buy Today even though no revenue details have been given again. Will have to wait for results. Well under the radar is this one.
Is that the results will be out in the beginning of May.
They will show the increase in commercializing during 2023,
and show more movement towards profit.
The impression I get is that great strides have been made,
and will show how undervalued the SP has been, and show
that a re-rating is justified. Am thinking of 20p initially.
Also expect a larger company may move to take-over.
imho- dyor
One can imagine the impact on revenue of Ondine as Steriwave gains recognition in hospitals throughout the world which adopt it as the preferred method to achieve huge reductions in fatalities
The resultant share price achievement, which is currently tiny, would be significant
Thank you for your note, Peter. We recognize that there are questions and are working to address this issue.
Https://www.britishbulls.com/SignalPage.aspx?lang=en&Ticker=obi.L
Tempting price, but can see even lower until they confirm income levels and orders in RNS
6.53-6.8p current low price
Entry into ICU market expands revenue potential
Following interest from Canadian Hospitals, Ondine prepares to enter the Intensive Care Unit (ICU) market
· Treatment of patients in ICUs would significantly expand Ondine's
potential market opportunity.
· Hundreds of thousands of patients are admitted to the ICU every year
in Canada alone, with an average stay of over four days.
6.655-7.08 current price
in my opinion this has to be a steal
"Points taken from 04/04/24 RNS:Ondine has a pipeline of investigational products in various stages of development.
Ondine's nasal decolonisation light-activated technology has a CE mark in Europe and the UK-CA mark, and is approved in Canada and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Light-activated antimicrobial products in development include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications."
The outcome of the clinical trials for regulatory approval (presumably FDA) may provide a short term boost. Hopefully, the upcoming full year results will contain positive updates as well as reassuring financial data.
Ondine Biomedical Inc on Monday reported that a study undertaken at the Mazankowski Alberta Heart Institute demonstrated a 32% reduction in cardiac surgical site infections through the use of its Steriwave product as a replacement for the antibiotic Mupirocin.
This comes after Steriwave was implemented on a pilot basis as a replacement for Mupirocin in June last year, the Vancouver-based life sciences company said.
Steriwave is a light-activated antimicrobial which employs patented nasal photodisinfection technology to eliminate bacteria, fungi and viruses located on human tissues.
According to Ondine, SSIs are "one of the most significant complications in cardiac surgery patients and are strongly associated with poorer prognosis".
Just last week, Ondine announced that Steriwave had been approved by HCA Healthcare UK for use in its healthcare facilities.
Shares in Ondine were up 1.0% at 7.57 pence each in London on Monday afternoon.
Agreed. Hence I only took a small position today. Been a string of good news recently and hopefully we can see things move forward from here
The issue for most investors is having no idea of the revenue from existing and new customers / hospitals to determine when the company will break even ending the risk of another diluting and heavily discounted fund raise.
Potential is good and I have bought shares but will not increase my holding when so little is known about the finances.
9000 this morning was a buy!
Just started my position here. All the recent news coming out are very positive but it doesn't seem to be getting any traction at all. I suppose everyone is worried about how much liquidity we have to see through phase 3. I'm going to be long here but this could be a nice takeover target imo
One can imagine the impact on revenue as it gains total acceptance as the way to achieve huge reductions in fatalities.
The resultant revenue of Ondine steriwave would be huge as hospitals throughout the world use it as the preferred method.
Commercialization is the key
Very positive endorsements.
This must bode well for commercialisation in the next 12 months.
My buy yesterday was shown as a sell